Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9383774 | Archivos de Bronconeumología | 2005 | 9 Pages |
Abstract
The mean cost was â¬1555.70. The costs of moderate and severe exacerbations were 4 and 12 times that of a mild exacerbation, respectively. Long-acting β2 agonists were less widely used than recommended by the guidelines for treatment of moderate and severe persistent asthma leading to asthma exacerbations.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
L. BorderÃas Clau, M. Zabaleta Murguionda, J.A. Riesco Miranda, C. Pellicer Ciscar, J.R. Hernández Hernández, T. Carrillo DÃaz, G. Lumbreras GarcÃa,